Special Session

Presidential Symposium II - EL11- RT for Oligometastatic Prostate Cancer Will Replace Systemic Therapy

10:15 AM - 11:45 AM
Location: Room W375e

Session Type: Special Session
0.00 AMA PRA Category 1 Credits™

In this session we will review and discuss the current role of metastasis-directed radiotherapy for oligometastatic prostate cancer. The session will begin with two experts reviewing the available evidence to support radiotherapy for oligometastatic prostate cancer, as well as the known limitations of the evidence, potential harm(s), and ongoing clinical trials exploring the impact of metastasis-directed therapy. This short didactic session will be followed by an interactive mock tumor board format using two patient cases to highlight the various and distinct disease states of oligometastatic prostate cancer and the potential role of radiotherapy, with or without systemic therapy. This interactive portion will include cases of newly-diagnosed treatment-na?ve M1 prostate cancer as well as oligometastatic disease detected on molecular imaging only in the setting of biochemical recurrence after radical therapy.

Case Presentation Topics:
Case Topic 1: De Novo Metastatic Hormone-Sensitive Prostate Cancer
Case Topic 2: Oligometastatic Recurrence After Definitive Therapy for Localized Prostate Cancer


Curtiland Deville, MD

Johns Hopkins University

Johns Hopkins: Associate Professor: Employee

Dr. Curtiland Deville is an Associate Professor in the Department of Radiation Oncology and Molecular Radiation Sciences at Johns Hopkins University School of Medicine. He serves as Clinical Director of Sibley Radiation Oncology, the future site of proton therapy for Johns Hopkins Medicine.

He is a graduate of Brown University’s Program in Liberal Medical Education and a past Doris Duke Clinical Research Fellow at the Yale Cancer Center. He completed his transitional year internship in internal medicine at Harbor Hospital Center and residency in radiation oncology at the Hospital of the University of Pennsylvania, where he joined the junior faculty as an Assistant Professor and served as clinical Chief of the Genitourinary and Sarcoma Services in the Department of Radiation Oncology.

Dr. Deville’s clinical and research focus is in treating patients with genitourinary malignancies and soft tissue sarcoma. He also has a research interest in physician workforce diversity as a means to addressing health disparities.

He is the current Chair of the American Society for Radiation Oncology (ASTRO) Committee on Health Equity, Diversity and Inclusion (CHEDI). He also serves on the American College of Radiology’s Commission for Women and Diversity, and American Society of Clinical Oncology’s Health Equity Committee.


Send Email for Curtiland Deville

Neha Vapiwala, MD

University of Pennsylvania Health System

Dr. Vapiwala is an Associate Professor and Vice Chair for Education in the Department of Radiation Oncology. She specializes in the management of patients with genitourinary (GU) cancers, serving as the department's first Chief of GU Oncology. She has served as the Principal Investigator of multiple therapeutic trials for prostate cancer patients, including a role as Project Leader on a Department of Defense Program Project grant investigating proton therapy. She has also secured extramural funding to develop prognostic and predictive biomarkers for novel radiosensitizers and molecular imaging tools, as well as to explore the effect of integrative medicine as a therapeutic intervention for disease- and treatment-related symptoms. Dr. Vapiwala also holds leadership positions in multiple national and cooperative group committees in GU oncology, and presently serves on the NCI Prostate Cancer Task Force as well as the ECOG-ACRIN GU Early Modality committee in the role of Co-Chair. She was also recently appointed to the editorial boards of JAMA Oncology and the International Journal of Proton Therapy.

Dr. Vapiwala also has a strong interest in medical education. In July 2017, she was promoted to the position of Assistant Dean of Students at Perelman School of Medicine, and serves on the Executive Committee of the National Association of Directors of Radiation Oncology Programs and as Vice Chair of the Accreditation Council for Graduate Medical Education's Residency Review Committee.

Dr. Vapiwala graduated from Johns Hopkins University with a double major in Biology and Hispanic Studies. Upon completing her undergraduate studies early, she taught high school math and science for a year before matriculating at the Perelman School of Medicine at the University of Pennsylvania on a full-tuition, merit-based scholarship. She completed her residency training including service as the Chief Resident in the Department of Radiation Oncology at University of Pennsylvania.


Send Email for Neha Vapiwala

Daniel Spratt, MD

University of Michigan

Dan Spratt, MD, is an Associate Professor in the Department of Radiation Oncology at the University of Michigan. He is a national leader in genitourinary and spinal malignancies. In addition to his medical training at Vanderbilt University where he obtained his medical degree, he completed his radiation oncology residency at Memorial Sloan Kettering Cancer Center. Dr. Spratt is the Chief of the Genitourinary Radiotherapy Program and Vice Chair of Clinical Research within the Department of Radiation Oncology. He also is the co-chair for the Genitourinary Division of Clinical Research for the Rogel Cancer Center, co-leader of the LAPS U10 cooperative group clinical trial program, is the founder and director the Spine Oncology Program at the University of Michigan, and co-chairs the radiobiology and Prostate Cancer Disparities working groups for the Prostate Cancer Foundation. He gives talks nationally and internationally on his work in prostate cancer, and serves on study sections for several federal and foundation programs. Dr. Spratt has published extensively in peer-reviewed journals and has received grant funding on the topics of prostate cancer and spinal malignancies. He has developed novel prognostic models to assess the aggressiveness of a patient’s cancer using not only clinical and pathologic features, but also genomic and imaging biomarkers. His laboratory focuses on the interaction of androgens and DNA repair in prostate cancer and methods to overcome radiation resistance. He runs novel phase I/II clinical trials to improve treatment outcomes and reduce side effects from cancer treatment.


Send Email for Daniel Spratt


Presidential Symposium II - EL11- RT for Oligometastatic Prostate Cancer Will Replace Systemic Therapy

Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Presidential Symposium II - EL11- RT for Oligometastatic Prostate Cancer Will Replace Systemic Therapy